NCT05508256
CAtheter-Based Ablation of Atrial Fibrillation Compared to Conventional Treatment in Patients With Heart Failure With Preserved Ejection Fraction
Recruiting · Phase 4 · Charite University, Berlin, Germany · registry updated 2023-03-06
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The objective of CABA-HFPEF is to test whether catheter ablation (CA) for atrial fibrillation (AF) can prevent adverse cardiovascular outcomes in patients with heart failure with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF).
Inclusion
- Age ≥18 years
- Signed written informed consent
- Clinical evidence of symptomatic heart failure (NYHA Class II-III)
- Paroxysmal or persistent atrial fibrillation (less than 24 months after first diagnosis, documented at least on one 12-lead ECG)
- Left ventricular ejection fraction (LVEF) 40-49%
- LVEF ≥ 50% with at least one of the following HFpEF echocardiography findings (any local measurement made during the screening epoch):
Exclusion
- Patient is unable or unwilling to provide infomed consent
- Patient is not suitable for rhythm control of AF
- Previous left atrial CA or surgical therapy of AF
- Acutely decompensated HF, NYHA IV (patients can be enrolled after stabilization)
- Valvular heart disease needing interventional or surgical treatment within 3 months
- Heart surgery planned within 3 months